Ashwagandha (Withania somnifera)根提取物和褪黑素改善成人睡眠质量的比较评价:一项前瞻性、随机、双盲、安慰剂对照研究。

IF 2.1 Q3 CLINICAL NEUROLOGY
Navya Movva, Jaising Salve, Kalpana Wankhede, Vaishali Thakare, Deepak Langade
{"title":"Ashwagandha (Withania somnifera)根提取物和褪黑素改善成人睡眠质量的比较评价:一项前瞻性、随机、双盲、安慰剂对照研究。","authors":"Navya Movva, Jaising Salve, Kalpana Wankhede, Vaishali Thakare, Deepak Langade","doi":"10.3390/clockssleep8020015","DOIUrl":null,"url":null,"abstract":"<p><p>Ashwagandha, a revered herb in Ayurvedic medicine for over 3000 years, is recognized for its potential benefits in regulating sleep and supporting overall vitality. This study evaluated the comparative effects of Ashwagandha root extract (ARE) and melatonin (MLT) on sleep quality in adults. In this prospective, randomized, double-blind, placebo-controlled trial, 200 men and women aged 18-50 years were randomized to receive ARE (300 mg twice daily; <i>n</i> = 50), MLT (3 mg/day; <i>n</i> = 50), a combination of ARE (600 mg/day) and MLT (3 mg/day; <i>n</i> = 50), or placebo (<i>n</i> = 50) for eight weeks. The primary outcome was the change in sleep onset latency (SOL) from baseline to week eight, measured by actigraphy. Secondary outcomes included actigraphy-based changes in total sleep time (TST), wake after sleep onset (WASO), and sleep efficiency (SE), as well as subjective measures such as the Pittsburgh Sleep Quality Index (PSQI) and the Hamilton Anxiety Scale (HAM-A). At week eight, SOL was significantly reduced across treatment groups, with the ARE-MLT (<i>p</i> < 0.0001) combination showing the greatest improvement. The combination group also demonstrated significant improvements in TST (<i>p</i> < 0.0001), WASO (<i>p</i> < 0.0001), and SE (<i>p</i> < 0.0001), whereas ARE and MLT monotherapy produced moderate but comparable benefits. Inferential analyses confirmed statistically significant improvements in objective and subjective sleep measures (<i>p</i> < 0.0001). Safety analyses indicated that mild adverse events occurred across all groups, with no clinically significant between-group differences. Overall, both Ashwagandha and melatonin improved sleep disturbances in adults, with combination therapy producing the most consistent and pronounced benefits.</p>","PeriodicalId":33568,"journal":{"name":"Clocks & Sleep","volume":"8 2","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108063/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative Evaluation of Ashwagandha (<i>Withania somnifera</i>) Root Extract and Melatonin for Improving Sleep Quality in Adults: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study.\",\"authors\":\"Navya Movva, Jaising Salve, Kalpana Wankhede, Vaishali Thakare, Deepak Langade\",\"doi\":\"10.3390/clockssleep8020015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ashwagandha, a revered herb in Ayurvedic medicine for over 3000 years, is recognized for its potential benefits in regulating sleep and supporting overall vitality. This study evaluated the comparative effects of Ashwagandha root extract (ARE) and melatonin (MLT) on sleep quality in adults. In this prospective, randomized, double-blind, placebo-controlled trial, 200 men and women aged 18-50 years were randomized to receive ARE (300 mg twice daily; <i>n</i> = 50), MLT (3 mg/day; <i>n</i> = 50), a combination of ARE (600 mg/day) and MLT (3 mg/day; <i>n</i> = 50), or placebo (<i>n</i> = 50) for eight weeks. The primary outcome was the change in sleep onset latency (SOL) from baseline to week eight, measured by actigraphy. Secondary outcomes included actigraphy-based changes in total sleep time (TST), wake after sleep onset (WASO), and sleep efficiency (SE), as well as subjective measures such as the Pittsburgh Sleep Quality Index (PSQI) and the Hamilton Anxiety Scale (HAM-A). At week eight, SOL was significantly reduced across treatment groups, with the ARE-MLT (<i>p</i> < 0.0001) combination showing the greatest improvement. The combination group also demonstrated significant improvements in TST (<i>p</i> < 0.0001), WASO (<i>p</i> < 0.0001), and SE (<i>p</i> < 0.0001), whereas ARE and MLT monotherapy produced moderate but comparable benefits. Inferential analyses confirmed statistically significant improvements in objective and subjective sleep measures (<i>p</i> < 0.0001). Safety analyses indicated that mild adverse events occurred across all groups, with no clinically significant between-group differences. Overall, both Ashwagandha and melatonin improved sleep disturbances in adults, with combination therapy producing the most consistent and pronounced benefits.</p>\",\"PeriodicalId\":33568,\"journal\":{\"name\":\"Clocks & Sleep\",\"volume\":\"8 2\",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2026-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108063/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clocks & Sleep\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/clockssleep8020015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clocks & Sleep","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/clockssleep8020015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

阿什瓦甘达是一种在阿育吠陀医学中受人尊敬的草药,已有3000多年的历史,被认为具有调节睡眠和维持整体活力的潜在益处。本研究比较了Ashwagandha根提取物(ARE)和褪黑素(MLT)对成人睡眠质量的影响。在这项前瞻性、随机、双盲、安慰剂对照试验中,200名年龄在18-50岁的男性和女性被随机分为三组,分别接受ARE (300 mg/天,n = 50)、MLT (3 mg/天,n = 50)、ARE (600 mg/天)和MLT (3 mg/天,n = 50)或安慰剂(n = 50)治疗,疗程为8周。主要结局是通过活动描记术测量从基线到第8周睡眠发作潜伏期(SOL)的变化。次要结果包括基于活动图的总睡眠时间(TST)、睡眠后觉醒(WASO)和睡眠效率(SE)的变化,以及匹兹堡睡眠质量指数(PSQI)和汉密尔顿焦虑量表(HAM-A)等主观测量。在第8周,各治疗组的SOL显著降低,其中ARE-MLT联合治疗(p < 0.0001)改善最大。联合治疗组在TST (p < 0.0001)、WASO (p < 0.0001)和SE (p < 0.0001)方面也有显著改善,而ARE和MLT单药治疗产生了中等但相当的益处。推断分析证实了客观和主观睡眠测量的统计学显著改善(p < 0.0001)。安全性分析表明,所有组均发生轻度不良事件,组间无临床显著差异。总的来说,Ashwagandha和褪黑素都能改善成年人的睡眠障碍,联合治疗产生最一致和显著的效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative Evaluation of Ashwagandha (Withania somnifera) Root Extract and Melatonin for Improving Sleep Quality in Adults: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study.

Ashwagandha, a revered herb in Ayurvedic medicine for over 3000 years, is recognized for its potential benefits in regulating sleep and supporting overall vitality. This study evaluated the comparative effects of Ashwagandha root extract (ARE) and melatonin (MLT) on sleep quality in adults. In this prospective, randomized, double-blind, placebo-controlled trial, 200 men and women aged 18-50 years were randomized to receive ARE (300 mg twice daily; n = 50), MLT (3 mg/day; n = 50), a combination of ARE (600 mg/day) and MLT (3 mg/day; n = 50), or placebo (n = 50) for eight weeks. The primary outcome was the change in sleep onset latency (SOL) from baseline to week eight, measured by actigraphy. Secondary outcomes included actigraphy-based changes in total sleep time (TST), wake after sleep onset (WASO), and sleep efficiency (SE), as well as subjective measures such as the Pittsburgh Sleep Quality Index (PSQI) and the Hamilton Anxiety Scale (HAM-A). At week eight, SOL was significantly reduced across treatment groups, with the ARE-MLT (p < 0.0001) combination showing the greatest improvement. The combination group also demonstrated significant improvements in TST (p < 0.0001), WASO (p < 0.0001), and SE (p < 0.0001), whereas ARE and MLT monotherapy produced moderate but comparable benefits. Inferential analyses confirmed statistically significant improvements in objective and subjective sleep measures (p < 0.0001). Safety analyses indicated that mild adverse events occurred across all groups, with no clinically significant between-group differences. Overall, both Ashwagandha and melatonin improved sleep disturbances in adults, with combination therapy producing the most consistent and pronounced benefits.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clocks & Sleep
Clocks & Sleep Multiple-
CiteScore
4.40
自引率
0.00%
发文量
0
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书